Results 81 to 90 of about 180,059 (262)
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundSmad nuclear interacting protein 1 (SNIP1) plays a critical role in cell proliferation, transformation of embryonic fibroblasts, and immune regulation. However, the role of SNIP1 in cardiac hypertrophy remains unclear.
Yu‐yan Lu +9 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 809-818, April 2025.Abstract Aims This study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light‐chain amyloidosis (AL) and hereditary (ATTRv) and wild‐type transthyretin amyloidosis (ATTRwt)].
Alessia Argirò +20 more
wiley +1 more source
The rewiring of cAMP/cGMP and LDH signalling drives cardiac hypertrophy in Pde5a −/− mice
Life Science AllianceThis discovery will be very useful in term of personalized medicine because Pde5a inhibitors should be administrated depending on the severity of cardiac hypertrophy.
Ana Gabriela de Oliveira do Rêgo +15 more
doaj +1 more source
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Nuclear receptor corepressor 1 represses cardiac hypertrophy
EMBO Molecular Medicine, 2019 The function of nuclear receptor corepressor 1 (NCoR1) in cardiomyocytes is unclear, and its physiological and pathological implications are unknown. Here, we found that cardiomyocyte‐specific NCoR1 knockout (CMNKO) mice manifested cardiac hypertrophy at
Chao Li +24 more
doaj +1 more source
Biomarkers of lung congestion and injury in acute heart failure
ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi +9 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Fueling Cardiac Hypertrophy [PDF]
Circulation Research, 2020 Timothy R, Matsuura +2 more
openaire +2 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source